Loading...
•
Mar 31, 2024
CRISPR Therapeutics Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Key Takeaways
CRISPR Therapeutics reported its Q1 2024 financial results, highlighted by a strong cash position of approximately $2.1 billion. The company is advancing its portfolio of clinical trials and nominated additional in vivo programs.
More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™.
Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™.
Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™.
Expanded pipeline with new pre-clinical programs utilizing lipid nanoparticle (LNP) mediated delivery to the liver for refractory hypertension and acute hepatic porphyria.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Grant Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics expects to broaden the number of patients that could potentially benefit from transformative gene-editing based therapies with multiple data read-outs in the next 12-18 months and to initiate clinical trials for CTX340 and CTX450 in the second half of 2025.
Positive Outlook
- Advancing portfolio of clinical trials across oncology, autoimmune, diabetes and cardiovascular indications.
- Nominating additional in vivo programs targeting both rare and common diseases to portfolio based on promising pre-clinical data.
- Initiating a clinical trial for CTX112 in systemic lupus erythematosus (SLE) in the first half of this year.
- Initiating a clinical trial for CTX131 in hematologic malignancies in the first half of this year.
- Expanding the liver-targeted in vivo pipeline.